We are boosting cell rejuvenation to treat currently incurable neurodegenerative and rare genetic diseases
Autophagy (from the Ancient Greek: ”self-eating”) is the cell’s main method for recycling damaged components and this process declines with age. There is compelling evidence that boosting autophagy leads to increased healthspan and lifespan, while impaired autophagy drives many serious diseases.
We are enhancing healthspan, by building an unbiased data-driven drug discovery engine
We’re letting our proprietary data guide us in new and unexpected directions to find better ways to restore autophagy. This approach allows us to uncover brand new biology and gives us new and fundamental insights into how the cell controls this process.
Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics
We’re pleased to report that we’ve further strengthened our team in Oxford.
There is a desperate need for novel therapies that can prevent the progressive neurodegeneration in debilitating diseases of ageing, such as Alzheimer’s, Parkinson’s and Huntington’s Disease.
It’s a busy time for Samsara Therapeutics as we move into our new purpose-built labs and offices in the Wood Centre for Innovation in Oxford.